Gilead Sciences (GILD) Stock Forecast & Price Target

Compare

13,786 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

GILD Analyst Ratings

Strong Buy

15 Buy

4 Hold

0 Sell

Based on 19 analysts giving stock ratings to

Gilead

Sciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

GILD Stock 12 Month Forecast

Average Price Target

$152.84

▼(-1.38% Downside)

Based on 19 Wall Street analysts offering 12 month price targets for Gilead Sciences in the last 3 months. The average price target is $152.84 with a high forecast of $177.00 and a low forecast of $118.00. The average price target represents a -1.38% change from the last price of $154.98.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"93":"$93","178":"$178","114.25":"$114.3","135.5":"$135.5","156.75":"$156.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":177,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$177.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":152.8421052631579,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$152.84</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":118,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$118.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[93,114.25,135.5,156.75,178],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,142.89,145.51384615384615,148.1376923076923,150.76153846153846,153.3853846153846,156.00923076923075,158.6330769230769,161.25692307692307,163.88076923076923,166.5046153846154,169.12846153846152,171.75230769230768,174.37615384615384,{"y":177,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,142.89,143.65554655870443,144.4210931174089,145.18663967611334,145.95218623481782,146.71773279352226,147.4832793522267,148.24882591093117,149.01437246963562,149.77991902834006,150.54546558704453,151.31101214574898,152.07655870445345,{"y":152.8421052631579,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,142.89,140.9753846153846,139.0607692307692,137.14615384615382,135.23153846153846,133.31692307692308,131.4023076923077,129.4876923076923,127.57307692307691,125.65846153846154,123.74384615384615,121.82923076923078,119.91461538461539,{"y":118,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":94.56,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.2,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.01,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.15,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.69,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 67,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.23,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.66,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 66,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.42,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.51,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.74,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":142.89,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$177.00

Average Price Target$152.84

Lowest Price Target$118.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Joseph Stringer

Needham

$170

Buy

9.69%

Upside

Assigned

02/11/26

Underappreciated Earnings Power: Why Strong HIV Momentum and Margin Expansion Support a Buy on Gilead

Tyler Van Buren

TD Cowen

$145→$160

Buy

3.24%

Upside

Reiterated

02/11/26

Buy Rating on Gilead: Solid Core Growth, Conservative Guidance, and Late-Stage Pipeline Upside Into 2026

Gregory Renza

Truist Financial

$145→$152

Buy

-1.92%

Downside

Reiterated

02/11/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Quest Diagnostics (NYSE: DGX), Exelixis (NASDAQ: EXEL) and Gilead Sciences (NASDAQ: GILD)

Terence Flynn

Morgan Stanley

$150→$171

Buy

10.34%

Upside

Reiterated

02/11/26

Gilead Sciences: HIV Franchise Strength, Yeztugo Ramp, and Solid 2026 Outlook Underpin Buy Rating and Positive Risk‑Reward

Mohit Bansal

Wells Fargo

$150→$165

Buy

6.47%

Upside

Reiterated

02/11/26

Gilead price target raised to $165 from $150 at Wells FargoGilead price target raised to $165 from $150 at Wells Fargo

Geoff Meacham

Citi

$156

Buy

0.66%

Upside

Reiterated

02/11/26

Reaffirming Gilead as a Buy: HIV Franchise Strength, Emerging Oncology Assets, and Strategic Capital Deployment Support $156 Target

Salveen Richter

Goldman Sachs

$115→$125

Hold

-19.34%

Downside

Reiterated

02/11/26

Balanced Outlook on Gilead: Solid Core Performance but Execution and Competitive Risks Justify Hold Rating

Chris Schott

J.P. Morgan

$150→$160

Buy

3.24%

Upside

Reiterated

02/11/26

Gilead Sciences (GILD) Gets a Buy from J.P. Morgan

Matthew Biegler

Oppenheimer

$128→$165

Buy

6.47%

Upside

Reiterated

02/11/26

Gilead price target raised to $165 from $128 at OppenheimerGilead price target raised to $165 from $128 at Oppenheimer

Tazeen Ahmad

Bank of America Securities

$154→$162

Buy

4.53%

Upside

Reiterated

02/11/26

Gilead price target raised to $162 from $154 at BofAGilead price target raised to $162 from $154 at BofA

Louise Chen

Scotiabank

$140→$177

Buy

14.21%

Upside

Reiterated

02/11/26

Scotiabank Keeps Their Buy Rating on Gilead Sciences (GILD)

Brian Skorney

Robert W. Baird

$108→$145

Hold

-6.44%

Downside

Reiterated

02/11/26

Gilead price target raised to $145 from $108 at BairdGilead price target raised to $145 from $108 at Baird

Evan Seigerman

BMO Capital

$150→$160

Buy

3.24%

Upside

Reiterated

02/10/26

Gilead price target raised to $160 from $150 at BMO CapitalGilead price target raised to $160 from $150 at BMO Capital

Brian Abrahams

RBC Capital

$103→$118

Hold

-23.86%

Downside

Reiterated

02/10/26

RBC Capital Keeps Their Hold Rating on Gilead Sciences (GILD)

Carter Gould

Cantor Fitzgerald

$135→$155

Buy

0.01%

Upside

Reiterated

02/10/26

Gilead Sciences (GILD) Receives a Buy from Cantor Fitzgerald

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Joseph Stringer

Needham

$170

Buy

9.69%

Upside

Assigned

02/11/26

Underappreciated Earnings Power: Why Strong HIV Momentum and Margin Expansion Support a Buy on Gilead

Tyler Van Buren

TD Cowen

$145→$160

Buy

3.24%

Upside

Reiterated

02/11/26

Buy Rating on Gilead: Solid Core Growth, Conservative Guidance, and Late-Stage Pipeline Upside Into 2026

Gregory Renza

Truist Financial

$145→$152

Buy

-1.92%

Downside

Reiterated

02/11/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Quest Diagnostics (NYSE: DGX), Exelixis (NASDAQ: EXEL) and Gilead Sciences (NASDAQ: GILD)

Terence Flynn

Morgan Stanley

$150→$171

Buy

10.34%

Upside

Reiterated

02/11/26

Gilead Sciences: HIV Franchise Strength, Yeztugo Ramp, and Solid 2026 Outlook Underpin Buy Rating and Positive Risk‑Reward

Mohit Bansal

Wells Fargo

$150→$165

Buy

6.47%

Upside

Reiterated

02/11/26

Gilead price target raised to $165 from $150 at Wells FargoGilead price target raised to $165 from $150 at Wells Fargo

Geoff Meacham

Citi

$156

Buy

0.66%

Upside

Reiterated

02/11/26

Reaffirming Gilead as a Buy: HIV Franchise Strength, Emerging Oncology Assets, and Strategic Capital Deployment Support $156 Target

Salveen Richter

Goldman Sachs

$115→$125

Hold

-19.34%

Downside

Reiterated

02/11/26

Balanced Outlook on Gilead: Solid Core Performance but Execution and Competitive Risks Justify Hold Rating

Chris Schott

J.P. Morgan

$150→$160

Buy

3.24%

Upside

Reiterated

02/11/26

Gilead Sciences (GILD) Gets a Buy from J.P. Morgan

Matthew Biegler

Oppenheimer

$128→$165

Buy

6.47%

Upside

Reiterated

02/11/26

Gilead price target raised to $165 from $128 at OppenheimerGilead price target raised to $165 from $128 at Oppenheimer

Tazeen Ahmad

Bank of America Securities

$154→$162

Buy

4.53%

Upside

Reiterated

02/11/26

Gilead price target raised to $162 from $154 at BofAGilead price target raised to $162 from $154 at BofA

Louise Chen

Scotiabank

$140→$177

Buy

14.21%

Upside

Reiterated

02/11/26

Scotiabank Keeps Their Buy Rating on Gilead Sciences (GILD)

Brian Skorney

Robert W. Baird

$108→$145

Hold

-6.44%

Downside

Reiterated

02/11/26

Gilead price target raised to $145 from $108 at BairdGilead price target raised to $145 from $108 at Baird

Evan Seigerman

BMO Capital

$150→$160

Buy

3.24%

Upside

Reiterated

02/10/26

Gilead price target raised to $160 from $150 at BMO CapitalGilead price target raised to $160 from $150 at BMO Capital

Brian Abrahams

RBC Capital

$103→$118

Hold

-23.86%

Downside

Reiterated

02/10/26

RBC Capital Keeps Their Hold Rating on Gilead Sciences (GILD)

Carter Gould

Cantor Fitzgerald

$135→$155

Buy

0.01%

Upside

Reiterated

02/10/26

Gilead Sciences (GILD) Receives a Buy from Cantor Fitzgerald

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Gilead Sciences

3 Months

xxx

Success Rate

12/14 ratings generated profit

Average Return

+10.66%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 85.71% of your transactions generating a profit, with an average return of +10.66% per trade.

1 Year

Courtney BreenBernstein

Success Rate

14/14 ratings generated profit

Average Return

+34.14%

a rating ―

Copying Courtney Breen's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +34.14% per trade.

2 Years

xxx

Success Rate

21/21 ratings generated profit

Average Return

+60.84%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +60.84% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GILD Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, GILD has received 43 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. GILD average Analyst price target in the past 3 months is 152.84.

Each month's total comprises the sum of three months' worth of ratings.

GILD Financial Forecast

GILD Earnings Forecast

Next quarter’s earnings estimate for GILD is $1.88 with a range of $1.73 to $2.07. The previous quarter’s EPS was $1.86. GILD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year GILD has Performed in-line its overall industry.

GILD Sales Forecast

Next quarter’s sales forecast for GILD is $6.90B with a range of $6.50B to $7.26B. The previous quarter’s sales results were $7.92B. GILD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year GILD has Performed in-line its overall industry.

GILD Stock Forecast FAQ

What is GILD’s average 12-month price target, according to analysts?

Based on analyst ratings, Gilead Sciences’s 12-month average price target is 152.84.

What is GILD’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for GILD, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is GILD a Buy, Sell or Hold?

Gilead Sciences has a consensus rating of Strong Buy which is based on 15 buy ratings, 4 hold ratings and 0 sell ratings.

What is Gilead Sciences’s price target?

The average price target for Gilead Sciences is 152.84. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $177.00 ,the lowest forecast is $118.00. The average price target represents -1.38% Decrease from the current price of $154.98.

What do analysts say about Gilead Sciences?

Gilead Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of GILD?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Gilead Sciences (GILD) Stock Forecast & Price Target

GILD Analyst Ratings

GILD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Gilead Sciences

GILD Analyst Recommendation Trends

GILD Financial Forecast

GILD Earnings Forecast

GILD Sales Forecast

GILD Stock Forecast FAQ

Detailed List of Analyst Forecasts